GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
This week on Pipeline Moves, we kick off by looking at a Phase II termination of an investigator-led trial of…
The University of Dundee in the UK is set to lead a clinical trial investigating whether existing medications can effectively…
The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently. Several biologics…
Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary…
US-based Insmed has shared more data from the Phase III ASPEN trial, showing that brensocatib also reduced the decline in…
Insmed’s stocks more than doubled after the company announced its lead-pipeline candidate brensocatib succeeded in a Phase III trial. The…
AstraZeneca and Daiichi Sankyo have reported high-level overall survival (OS) results from the Phase III TROPION-Lung01 clinical trial of datopotamab deruxtecan…
Sanofi has announced positive outcomes from a Phase II clinical trial of rilzabrutinib, an oral treatment for adults with uncontrolled…
GSK has announced positive data from two Phase III trials of its asthma candidate depemokimab. The pharma giant announced the…